We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.

The most recent trading session ended with Viking Therapeutics, Inc. (VKTX ... while the tech-heavy Nasdaq depreciated by 0.9%. The company's stock has dropped by 22.79% in the past month ...

On the other hand, the Dow registered a loss of 0.06%, and the technology-centric Nasdaq increased by 1.24%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to ...

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. And although it's ...

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX).

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and efficacy of the oral version of its investigational obesity drug VK2735.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...